Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping

• Published in: Journal of medicinal chemistry Vol. 60; no. 11; pp. 4636 - 4656
• Main Authors: Juchum, Michael, Günther, Marcel, Döring, Eva, Sievers-Engler, Adrian, Lämmerhofer, Michael, Laufer, Stefan
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 08.06.2017; Amer Chemical Soc
• Subjects: Binding Sites; Chemistry, Medicinal; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Imidazoles - chemistry; Imidazoles - pharmacology; Inhibitory Concentration 50; Life Sciences & Biomedicine; Molecular Docking Simulation; Mutation; Pharmacology & Pharmacy; Science & Technology; Structure-Activity Relationship; CELL LUNG-CANCER; ACTIVATED PROTEIN-KINASE; AMPLIFICATION; FACTOR RECEPTOR MUTATIONS; MAP KINASE; ACQUIRED-RESISTANCE; SENSITIVITY; TYROSINE KINASE INHIBITOR; T790M; AZD9291
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.7b00178

The high genomic instability of non-small cell lung cancer tumors leads to the rapid development of resistance against promising EGFR tyrosine kinase inhibitors (TKIs). A recently detected triple mutation compromises the activity of the gold standard third-generation EGFR inhibitors. We have prepared a set of trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif as a new structural class of EGFR inhibitors by a target hopping approach from p38α MAPK inhibitor templates. On the basis of an iterative approach of docking, compound preparation, biological testing, and SAR interpretation, robust and flexible synthetic routes were established. As a result, we report two reversible inhibitors 11d and 11e of the clinically challenging triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range. Furthermore, we developed a kinome selective irreversible inhibitor 45a with an IC50 value of 1 nM against the EGFR L858R/T790M double mutant. Target binding kinetics and metabolic stability data are included. These potent mutant EGFR inhibitors may serve as a basis for the development of structurally novel EGFR probes, tools, or candidates.